NASDAQ: VTRS | Healthcare / Drug Manufacturers / USA |
9.69 | +0.0800 | +0.83% | Vol 8.83M | 1Y Perf -12.08% |
Dec 6th, 2023 16:00 DELAYED |
BID | 9.66 | ASK | 9.70 | ||
Open | 9.64 | Previous Close | 9.61 | ||
Pre-Market | - | After-Market | 9.60 | ||
- - | -0.09 -0.93% |
Target Price | 12.89 | Analyst Rating | Moderate Sell 3.60 | |
Potential % | 33.02 | Finscreener Ranking | ★★★ 49.00 | |
Insiders Trans % 3/6/12 mo. | -/100/100 | Value Ranking | ★★+ 47.98 | |
Insiders Value % 3/6/12 mo. | -/100/100 | Growth Ranking | ★★+ 49.59 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/100/100 | Income Ranking | ★★ 37.21 | |
Price Range Ratio 52W % | 25.96 | Earnings Rating | — | |
Market Cap | 11.62B | Earnings Date | 7th Nov 2023 | |
Alpha | -0.03 | Standard Deviation | 0.11 | |
Beta | 1.09 |
Today's Price Range 9.629.79 | 52W Range 8.7412.40 | 5 Year PE Ratio Range -10.80770.30 |
Summary:
Buy
Technical Indicators: | Buy |
Moving Averages: | Buy |
Performance | |||
---|---|---|---|
1 Week | 5.56% | ||
1 Month | 6.13% | ||
3 Months | -3.10% | ||
6 Months | -0.21% | ||
1 Year | -12.08% | ||
3 Years | - | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -2.53 | |||
ROE last 12 Months | 3.99 | |||
ROA (5Y Avg) | -0.68 | |||
ROA last 12 Months | 1.53 | |||
ROC (5Y Avg) | 1.49 | |||
ROC last 12 Months | 2.90 | |||
Return on invested Capital Q | 1.20 | |||
Return on invested Capital Y | -0.35 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 1.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
18.30 | ||||
0.76 | ||||
1.18 | ||||
4.40 | ||||
7.10 | ||||
2.74 | ||||
-1.06 | ||||
15.82 | ||||
33.95B | ||||
Forward PE | - | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.70 | ||||
1.60 | ||||
0.49 | ||||
1.02 | ||||
2.90 | ||||
Leverage Ratio | 2.60 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
37.10 | ||||
10.40 | ||||
27.70 | ||||
0.20 | ||||
8.62 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
12.39B | ||||
10.21 | ||||
15.57 | ||||
7.31 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
4.00 | ||||
0.48 | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | 0.74 | 0.78 | 5.41 |
Q02 2023 | 0.71 | 0.75 | 5.63 |
Q01 2023 | 0.69 | 0.78 | 13.04 |
Q04 2022 | 0.69 | 0.69 | 0.00 |
Q03 2022 | 0.82 | 0.86 | 4.88 |
Q02 2022 | 0.81 | 0.88 | 8.64 |
Q01 2022 | 0.81 | 0.93 | 14.81 |
Q04 2021 | 0.82 | 0.80 | -2.44 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
- | - | - | - |
- | - | - | - |
- | - | - | - |
- | - | - | - |
Next Report Date | - |
Estimated EPS Next Report | 0.74 |
Estimates Count | 4 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 8.83M |
Shares Outstanding | 1.20M |
Shares Float | 1.20B |
Trades Count | 39.36K |
Dollar Volume | 85.64M |
Avg. Volume | 8.75M |
Avg. Weekly Volume | 8.92M |
Avg. Monthly Volume | 8.64M |
Avg. Quarterly Volume | 8.69M |
Viatris Inc. (NASDAQ: VTRS) stock closed at 9.69 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 8.83M shares and market capitalization of 11.62B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 40000 people. Viatris Inc. CEO is Michael Goettler.
The one-year performance of Viatris Inc. stock is -12.08%, while year-to-date (YTD) performance is -12.94%. VTRS stock has a five-year performance of %. Its 52-week range is between 8.74 and 12.3993, which gives VTRS stock a 52-week price range ratio of 25.96%
Viatris Inc. currently has a PE ratio of 18.30, a price-to-book (PB) ratio of 0.76, a price-to-sale (PS) ratio of 1.18, a price to cashflow ratio of 4.40, a PEG ratio of -, a ROA of 1.53%, a ROC of 2.90% and a ROE of 3.99%. The company’s profit margin is 8.62%, its EBITDA margin is 27.70%, and its revenue ttm is $12.39 Billion , which makes it $10.21 revenue per share.
Of the last four earnings reports from Viatris Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.74 for the next earnings report. Viatris Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Viatris Inc. is Moderate Sell (3.6), with a target price of $12.89, which is +33.02% compared to the current price. The earnings rating for Viatris Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Viatris Inc. has a dividend yield of 4.00% with a dividend per share of $0.48 and a payout ratio of -%.
Viatris Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 21.56, ATR14 : 0.23, CCI20 : 168.95, Chaikin Money Flow : 0.02, MACD : 0.04, Money Flow Index : 63.31, ROC : 4.80, RSI : 58.22, STOCH (14,3) : 77.94, STOCH RSI : 0.85, UO : 61.73, Williams %R : -22.06), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Viatris Inc. in the last 12-months were: Andrew Cuneo (Option Excercise at a value of $0), Anthony Mauro (Option Excercise at a value of $0), Brian Roman (Option Excercise at a value of $0), Der Meer Mohr Pauline Van (Option Excercise at a value of $0), Dillon JoEllen Lyons (Option Excercise at a value of $0), Harry A. Korman (Option Excercise at a value of $0), James M. Kilts (Option Excercise at a value of $0), Mark W. Parrish (Option Excercise at a value of $0), Melina E. Higgins (Option Excercise at a value of $0), Michael Goettler (Option Excercise at a value of $0), Paul B. Campbell (Option Excercise at a value of $0), Pauline F.M. van der Meer Mohr (Option Excercise at a value of $0), Rajiv Malik (Option Excercise at a value of $0), Richard A. Mark (Option Excercise at a value of $0), Robert J. Coury (Option Excercise at a value of $0), Sanjeev Narula (Option Excercise at a value of $0), Wyllie Don Cornwell (Option Excercise at a value of $0), Xiangyang (Sean) Ni (Option Excercise at a value of $0), Xiangyang (Sean) Ni (Sold 26 428 shares of value $268 324 ), Xiangyang Ni (Option Excercise at a value of $0), Xiangyang Ni (Sold 11 491 shares of value $128 363 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Sell | Hold | Hold |
The new entity will largely be led by Pfizer executives and will be registered in Delaware. The new entity is anticipated to leverage the stand-alone Mylan infrastructure consisting of roughly 55 manufacturing and research and development facilities and that were largely acquired, including Matrix Laboratories and the generics business of Germany-based Merck KGaA. The combined portfolio will consist of the mature Upjohn drugs with notably better economics and Mylan's portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines, including EpiPen (treatment for anaphylaxis acquired through the Merck KGaA transaction). Unlike its generic peers, the company has made the most progress on the biosimilar front.
CEO: Michael Goettler
Telephone: +1 724 514-1800
Address: 1000 Mylan Boulevard, Canonsburg 15317, PA, US
Number of employees: 40 000
Wed, 08 Nov 2023 11:01 GMT Analysts Conflicted on These Healthcare Names: Viatris (VTRS), Globus Medical (GMED) and Gilead Sciences (GILD)
- TipRanks. All rights reserved.Tue, 08 Aug 2023 07:16 GMT Viatris (VTRS) Receives a Sell from Barclays
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.